All our compounds are protected by international patent.
The international PTC/EP2012/055570 patent request, has been approved as number WO2012130912.
Currently, the patent has been granted in the following countries:
- USA, US9440966 (B2) (pdf)
- Europe, EP2691394 (B1)
- Japan, JP6049216 (B2) (pdf)
- Canada, 2,831,716
- Australia, AU2012234230 (B2) (pdf)
- Russia, RU2615136 (C2) (pdf)
- Israel, IL228630 (pdf)
- South Korea, KR101784284 (B1) (pdf)
- Mexico, MX349254 (pdf)
In addition, the international patent request has entered the regional phase in China, Brazil and India among others.
The use of all the compounds is protected for the treatment of the metabolic syndrome in general and for specific etiologies associated with the syndrome including diabetes, hypertension, dyslipidemia, obesity, hepatic steatosis and NASH.